Back to Search
CHRISTOPHER LEE, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1346823655IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
303365(NC)
CMS Specialties
PrimaryHOSPITALIST
Education
OTHER
Class of 2021
Research & Publications (20)
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.
PMID 19252526·Oncogene·2009
7-preclinical
Cytotoxic phenanthrenequinones and 9,10-dihydrophenanthrenes from Calanthe arisanensis.
PMID 19193043·J Nat Prod·2009
8-other
Patient-reported outcomes of breast reconstruction after mastectomy: a systematic review.
PMID 19651073·J Am Coll Surg·2009
1-meta
Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer.
PMID 19096310·J Thorac Oncol·2009
3-trial
Cytotoxic calanquinone A from Calanthe arisanensis and its first total synthesis.
PMID 18640035·Bioorg Med Chem Lett·2008
8-other
Recognizing thyrotoxicosis in a patient with bipolar mania: a case report.
PMID 18284661·Ann Gen Psychiatry·2008
8-other
Proposed structural models of human factor Va and prothrombinase.
PMID 17973648·J Thromb Haemost·2008
8-other
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
PMID 18473996·Rev Recent Clin Trials·2007
6-review
Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1).
PMID 17301694·Pharmacogenet Genomics·2007
8-other
Current and evolving treatment options for limited stage small cell lung cancer.
PMID 16462186·Curr Opin Oncol·2006
6-review
Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy.
PMID 17239295·Clin Lung Cancer·2006
6-review
NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: the Atherosclerosis Risk in Communities study.
PMID 17108813·Pharmacogenet Genomics·2006
8-other
Evidence for nucleosome depletion at active regulatory regions genome-wide.
PMID 15247917·Nat Genet·2004
8-other
Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.
PMID 12820813·Pharmacotherapy·2003
8-other
Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.
PMID 12698304·Eur J Clin Pharmacol·2003
3-trial
Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.
PMID 12520632·J Clin Pharmacol·2003
3-trial
Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.
PMID 12426520·Clin Pharmacol Ther·2002
8-other
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
PMID 11927841·Pharmacogenetics·2002
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 100 EASTOWNE DR
CHAPEL HILL, NC 27514 - Phone
- (984) 974-4462
Quick Facts
- NPI
- 1346823655
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 5
- Publications
- 20
Are you this provider?
Claim Your Profile